Agenus vs Arcus Biosciences
Arcus Biosciences is the larger business, with $247m of revenue in fiscal 2025 against $114m for Agenus (2.2 times as much). Agenus grew faster (10.4% against -4.3%). Agenus kept more of each dollar of sales as profit: a net margin of -0.1% against -142.9%.
| Latest fiscal year | AgenusAGEN, 2025 | Arcus BiosciencesRCUS, 2025 |
|---|---|---|
| Revenue | $114m | $247m |
| Revenue growth | 10.4% | -4.3% |
| Net income | −$101,000 | −$353m |
| Operating margin | -17.7% | -156.3% |
| Net margin | -0.1% | -142.9% |
| Return on equity | — | -63.3% |
| Free cash flow | −$77.2m | −$484m |
| Cash | $3.0m | $222m |
| Total debt | $45.5m | $100m |
| Debt to equity | — | 15.8% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 81 | 601 |
| Market value | $284m | $2.39bn |
| Price vs our value range | — | — |
| Moat score | 34 (Weak) | 10 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 0 sales |